The Food and Drug Administration yesterday approved the first continuous glucose monitoring system with a fully implantable sensor, designed to measure glucose levels in adults with diabetes for up to 90 days. Once implanted under the skin during an outpatient procedure, the sensor sends information to a mobile app to alert users if glucose levels are too high or too low. “The FDA is committed to advancing novel products that leverage digital technology to improve patient care,” said FDA Commissioner Scott Gottlieb, M.D.

Related News Articles

Perspective
What do New York-Presbyterian, Henry Ford Health System of Detroit, and Children’s Hospital Los Angeles all have in common?  
Headline
The Federal Communications Commission today voted unanimously to approve a notice of proposed rulemaking to establish a new $100 million “Connected Care Pilot…
Headline
The AHA today on Capitol Hill convened a panel of post-acute care leaders to brief lawmakers and their staff about the value these facilities provide to…
Headline
The Federal Communications Commission tomorrow is expected to vote on a notice of proposed rulemaking to establish a new $100 million “Connected Care Pilot…
Blog
AHA staff recently visited two rural hospitals to see and hear firsthand how leaders are engaging in innovative practices to increase accessibility and…
Insights and Analysis
AHA Senior Vice President and Chief Medical Officer Jay Bhatt, D.O., and Shantanu Agrawal, M.D., president and CEO of the National Quality Forum, highlight a…